Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 15/20 | 0.57 |
| ▸ | CTSS | P25774 | 7/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3989541 | 1.00 | CTSK (0.57) | CTSKCTSSATMCTSLCTSB | |
| SCHEMBL3890865 | 1.00 | CTSK (0.57) | CTSKCTSSATMCTSLCTSB | |
| SCHEMBL2400972 | 0.88 | CTSK (0.56) | CTSKCTSSATMCTSLCTSB | |
| SCHEMBL13446080 | 0.88 | CTSK (0.56) | CTSKCTSSATMCTSLCTSB | |
| SCHEMBL1519855 | 0.87 | PPARG (0.51) | CTSKCTSSATMCTSLCTSB | |
| SCHEMBL1519854 | 0.87 | PPARG (0.51) | CTSKCTSSATMCTSLCTSB | |
| SCHEMBL1519981 | 0.87 | PPARG (0.51) | CTSKCTSSATMCTSLCTSB | |
| SCHEMBL31341263 | 0.87 | CTSK (0.51) | CTSKCTSSCTSLCTSBMEN1 | |
| SCHEMBL762688 | 0.86 | CTSK (0.57) | CTSKCTSSATMCTSLCTSB | |
| SCHEMBL12029033 | 0.86 | CTSK (0.51) | CTSKCTSSATMCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250064789-A1 | KETOAMIDE DERIVATIVES AND PHARMACEUTICAL USES THEREOF | WESTVAC BIOPHARMA CO., LTD. (CN) | 2025-02-27 | — | — | US | disclosed |
| EP-4488264-A1 | KETO AMIDE DERIVATIVES AND PHARMACEUTICAL USE THEREOF | WestVac Biopharma Co., Ltd. (CN) | 2025-01-08 | — | — | EP | disclosed |
| CN-116693447-B | Ketone amide derivative and pharmaceutical application thereof | 成都威斯克生物医药有限公司 | 2024-08-13 | — | — | CN | disclosed |
| WO-2023165334-A1 | KETO AMIDE DERIVATIVES AND PHARMACEUTICAL USE THEREOF | 成都威斯克生物医药有限公司 | 2023-09-07 | — | — | WO | disclosed |
| CN-116693447-A | Ketone amide derivative and pharmaceutical application thereof | 成都威斯克生物医药有限公司 | 2023-09-05 | — | — | CN | disclosed |
| EP-0975600-A1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS ANTITHROMBOTIC AGENTS | Akzo Nobel N.V. (NL) | 2000-02-02 | — | — | EP | disclosed |
| WO-1998047876-A1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS ANTITHROMBOTIC AGENTS | AKZO NOBEL N.V. (NL) | 1998-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250064789-A1 | KETOAMIDE DERIVATIVES AND PHARMACEUTICAL USES THEREOF | ACE2, ACE, PKD2 | CTSK 866/4885CTSS 772/4885ATM 4579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.